Table 1 Characteristics of SLE patients
SLE patients (n = 284) | |
|---|---|
Transforming grow factor β1, pg/ml | 3164 ± 2652 |
Age, years | 50 ± 12 |
Female, n (%) | 261 (92) |
Body mass index, kg/m2 | 28 ± 6 |
Abdominal circumference, cm | 93 ± 14 |
Hip circumference, cm | 103 ± 12 |
Waist-to-hip ratio | 0.90 ± 0.07 |
Systolic pressure, mmHg | 127 ± 20 |
Diastolic pressure, mmHg | 79 ± 11 |
Cardiovascular co-morbidity | |
Smoking, n (%) | 69 (24) |
Diabetes, n (%) | 16 (6) |
Hypertension, n (%) | 111 (39) |
Obesity, n (%) | 85 (30) |
Statins, n (%) | 72 (25) |
Aspirin, n (%) | 80 (29) |
cIMT, µm | 628 ± 109 |
Carotid plaque, n (%) | 99 (36) |
SLE-related data | |
Disease duration, years | 16 (7–24) |
CRP, mg/dl | 2.0 (0.8–4.4) |
SDI | 1 (0–2) |
SDI ≥ 1, n (%) | 191 (68) |
Katz Index | 2 (1–4) |
Katz ≥ 3, n (%) | 126 (44) |
SLEDAI | 2 (0–4) |
SLEDAI categories, n (%) | |
No activity, n (%) | 109 (40) |
Mild, n (%) | 107 (39) |
Moderate, n (%) | 41 (15) |
High, n (%) | 10 (4) |
Very High, n (%) | 4 (1) |
Auto-antibody profile | |
Anti-DNA positive, n (%) | 151 (67) |
ENA positive, n (%) | 164 (69) |
Anti-SSA, n (%) | 55 (35) |
Anti-SSB, n (%) | 36 (21) |
Anti-RNP, n (%) | 64 (28) |
Anti-Sm, n (%) | 24 (10) |
Anti-ribosome | 13 (9) |
Anti-nucleosome | 32 (22) |
Anti-histone | 22 (15) |
Antiphospholipid syndrome, n (%) | 43 (16) |
Antiphospholipid autoantibodies, n (%) | 61 (32) |
Lupus anticoagulant, n (%) | 51 (28) |
ACA IgM, n (%) | 22 (11) |
ACA IgG, n (%) | 39 (20) |
Anti beta2 glycoprotein IgM, n (%) | 19 (10) |
Anti beta2 glycoprotein IgG, n (%) | 28 (15) |
C3, mg/dl | 130 ± 40 |
C4, mg/dl | 21 ± 12 |
Current prednisone, n (%) | 140 (50) |
Prednisone, mg/day | 5 (5–7.5) |
Hydroxychloroquine, n (%) | 194 (69) |
Methotrexate, n (%) | 31 (11) |
Mycophenolate mofetil, n (%) | 31 (11) |
Azathioprine, n (%) | 43 (15) |
Rituximab, n (%) | 8 (3) |
Belimumab, n (%) | 8 (3) |